The major human and mouse granzymes are structurally and functionally divergent

Dion Kaiserman,1 Catherina H. Bird,1 Jiuru Sun,1 Antony Matthews,1 Kheng Ung,1 James C. Whisstock,1,2 Philip E. Thompson,3 Joseph A. Trapani,4 and Phillip I. Bird1

1Department of Biochemistry and Molecular Biology and 2Victorian Bioinformatics Consortium, Monash University, Victoria 3800, Australia
3Department of Medicinal Chemistry, Victorian College of Pharmacy, Monash University, Parkville 3052, Australia
4Peter MacCallum Cancer Institute, Melbourne 8006, Australia

Approximately 2% of mammalian genes encode proteases. Comparative genomics reveals that those involved in immunity and reproduction show the most interspecies diversity and evidence of positive selection during evolution. This is particularly true of granzymes, the cytotoxic proteases of natural killer cells and CD8+ T cells. There are 5 granzyme genes in humans and 10 in mice, and it is suggested that granzymes evolve to meet species-specific immune challenge through gene duplication and more subtle alterations to substrate specificity.

We show that mouse and human granzyme B have distinct structural and functional characteristics. Specifically, mouse granzyme B is 30 times less cytotoxic than human granzyme B and does not require Bid for killing but regains cytotoxicity on engineering of its active site cleft. We also show that mouse granzyme A is considerably more cytotoxic than human granzyme A. These results demonstrate that even “orthologous” granzymes have species-specific functions, having evolved in distinct environments that pose different challenges.

Introduction

Granzymes are cytotoxic serine proteases used by cytotoxic lymphocytes (CLs) to destroy virus-infected and malignant cells. They are delivered into the cytoplasm of the target cell by the pore-forming protein perforin. Once inside the target cell, granzymes cleave specific proteins and trigger apoptosis (for review see Russell and Ley, 2002).

Humans have 5 granzymes (A, B, H, K, and M), whereas mice have 10 granzymes, having duplicated the ancestral granzyme B/H gene. There are 5 granzyme genes in humans and 10 in mice, and it is suggested that granzymes evolve to meet species-specific immune challenge through gene duplication and more subtle alterations to substrate specificity.

D. Kaiserman and C.H. Bird contributed equally to this paper.
Correspondence to Phillip I. Bird: phil.bird@med.monash.edu.au
Abbreviations used in this paper: CL, cytotoxic lymphocyte; IAP, inhibitor of apoptosis protein; MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; RCL, reactive center loop; SLO, streptolysin O; wt, wild-type.

The online version of this article contains supplemental material.
Without detailed comparative knowledge of the characteristics of human and mouse granzymes, data from mice cannot be extrapolated with confidence to humans. Here, we show that the cytotoxicity, substrate preferences, and inhibitor interactions of hGrB and mGrB are substantially different. We also extend the study of Bell et al. (2003) to show that hGrA and mGrA have markedly different cytotoxic potential. Such differences probably reflect the two species’ response to differing immune evolutionary pressure.

**Results**

**hGrB is more cytotoxic than mGrB**

Granzyme cytotoxicity can be studied in vitro by adding purified perforin and granzyme to cultured cells and monitoring cell survival (Fig. S1, available at http://www.jcb.org/cgi/content/full/jcb.200606073/DC1). Keeping the concentration of perforin constant, granzyme cytotoxicity is quantitated using a dose–response approach, in which the amount of enzyme required to kill 50% of the cells (EC50) is measured (Sun et al., 2004). Initial experiments using this system with either human or mouse cells showed that hGrB is substantially more cytotoxic than mGrB.

This apparent difference in cytotoxicity between mGrB and hGrB was confirmed using several different targets, as cell type–dependent differences in susceptibility to granzymes have been reported (Pardo et al., 2002). In one human cell line and three mouse cell lines examined in detail, hGrB was consistently more cytotoxic than mGrB (Fig. 1). With the exception of

**mGrB and hGrB have distinct substrate profiles and cytotoxic mechanisms.**

(A) mGrB inefficiently cleaves an optimal hGrB peptide substrate. Michaelis plots of peptide substrate hydrolysis by human (h) and mouse (m) GrB. Calculated specificity constants for each enzyme–substrate pair are tabulated below the plots. (B) mGrB inefficiently cleaves Bid. 35S-labeled mouse procaspase 3 or mouse Bid were incubated with hGrB or mGrB at 37°C for 30 min. 100 μM z-VAD was included in parallel reactions to prevent the second step in caspase 3 activation. Products were separated by 15% SDS-PAGE and visualized by fluorography. (C) mGrB does not require Bid to kill cells. Bid+/+ or Bid−/− (solid line) or Bid+/− (dashed line) mouse B cell lymphomas (Waterhouse et al., 2005) were incubated for 1 h with hGrB or mGrB in the presence of perforin. Cell survival was assessed after 24 h by MTT assay. EC50 values from replicate experiments are indicated below.
YAC-1, cells were 10–60-fold more sensitive to hGrB (Fig. 1). Killing of mouse YAC-1 cells required similarly high levels of hGrB or mGrB, suggesting that a key substrate is low or absent in these cells. mGrB was also 30-fold less effective in killing mouse lymphoma cells (Fig. 2 C).

To test whether poorer uptake of mGrB explains its inefficient killing, we compared accumulation of fluoresceininated mGrB and hGrB in Jurkat cells (Bird et al., 2005). No impairment in the rate or extent of accumulation of mGrB versus hGrB was noted in these cells (Fig. S2, available at http://www.jcb.org/cgi/content/full/jcb.200606073/DC1) or in the mouse P815 and lymphoma cell lines used in this study. The differences in cytotoxicity between mGrB and hGrB also remained when the bacterial porin, streptolysin O (SLO) was used instead of perforin (Fig. 1 C). SLO admits proteins directly to the cytoplasm via transient plasma membrane pores (Walev et al., 2001) and provides a perforin-independent mechanism for granzyme uptake, as shown by its ability to deliver mutant granzymes that cannot be delivered by perforin (Bird et al., 2005). The fact that mGrB killing is as inefficient in SLO as it is in perforin suggests that there is no restriction in perforin-mediated delivery of mGrB. Thus, differences in uptake or delivery of hGrB and mGrB do not explain their markedly different cytotoxic potential.

**mGrB-mediated cytotoxicity does not require Bid**

To investigate the basis for the differences in cytotoxicity between mGrB and hGrB, we compared their activities on peptide substrates and on the natural substrates procaspase 3 and Bid (Metkar et al., 2003; Waterhouse et al., 2005). Combinatorial peptide substrate analysis has identified the peptide IleGluXxxAsp as an optimal recognition and cleavage sequence for hGrB and rat GrB (Thornberry et al., 1997; Harris et al., 1998). This appears in human and mouse Bid, and both are cleaved at this site by hGrB (Pinkoski et al., 2001). Although mGrB cleaves Bid (Thomas et al., 2001), the cleavage site has not been determined. A similar P4–P1 cleavage sequence is present on procaspase 3, but the downstream (P’) sequence differs from Bid. The nomenclature of cleavage site positions of a protease substrate follows Schechter and Berger (1967). The protease cleaves the peptide bond between P1 and P1′. Adjacent residues in the N-terminal direction are numbered P2, P3, P4, etc. On the carboxyl side of the cleavage site, residues are numbered P2′, P3′, P4′, etc. The P1 residue is accommodated in the S1 pocket of the catalytic cleft, the P2 residue is accommodated in the S2 pocket, and so forth.

mGrB and hGrB both cleaved the small peptide substrate Boc-AlaAlaAsp-thio benzyl ester (AAD-sbzl) with similar efficiency (Fig. 2 A, right), consistent with their known Aspase activities, indicating that their apparent functional distinctions are not due to differences in ability to hydrolyse a P1(Asp)-P1′ bond. As expected, hGrB also efficiently cleaved IleGluThrAsp-pNA (IETD-pNA; Fig. 2 A, left). In contrast, mGrB hydrolyzed IETD-pNA 30-fold less efficiently than hGrB (Fig. 2 A, left), suggesting that it cannot comfortably accommodate this peptide in its substrate binding pocket.

The markedly inferior ability of mGrB to cleave IETD-pNA also suggested that it would not cleave full-length Bid or procaspase 3 efficiently. To test this, we produced 35S-labeled mouse Bid and mouse procaspase 3 and incubated the protein with hGrB or mGrB. Under these conditions, complete cleavage of Bid was achieved in 25 nM hGrB, whereas 2 μM mGrB failed to completely cleave Bid (Fig. 2 B, right). Thus, mGrB cleaves Bid 80–100-fold less efficiently than hGrB. In contrast, the two granzymes cleaved procaspase 3 with similar efficiency (Fig. 2 B, left), suggesting that other factors such as P′ residues also influence cleavage (Table I and Fig. 3).

Previous studies using hGrB have indicated that Bid cleavage is a key event in GrB-mediated apoptosis (Goping et al., 2003; Sutton et al., 2003; Waterhouse et al., 2005). GrB initiates procaspase 3 activation by cleaving it once, but full activation requires a second cleavage, autocatalytically or via another caspase. This is illustrated in Fig. 2 B and Fig. S3 (available at http://www.jcb.org/cgi/content/full/jcb.200606073/DC1) by the inclusion of the caspase inhibitor z-VAD in the reactions. In vivo, this second cleavage step is prevented by inhibitor of apoptosis protein (IAP) bound to caspase 3 and will not occur unless IAP is displaced by Smac/Diablo released from mitochondria by Bid (Goping et al., 2003; Sutton et al., 2003). Thus, in the absence of Bid, hGrB cannot drive full caspase 3 activation.

To examine the importance of Bid in mGrB-mediated apoptosis, we compared the ability of hGrB and mGrB to kill mouse cells lacking Bid. As reported previously (Waterhouse et al., 2005),

---

**Table I. Cleavage of Bid and phage display consensus peptides**

| Substratea | mGrB | hGrB |
|------------|------|------|
|            | $k_{cat}$ | $K_m$ | $k_{cat}/K_m$ | $k_{cat}$ | $K_m$ | $k_{cat}/K_m$ |
| Abz-EPD-I-SESQK(dpnp)S (wt Bid cleavage site) | 0.049 ± 0.004 | 30.88 ± 2.48 | 1,575 ± 172 | 1.32 ± 0.09 | 18.96 ± 2.45 | 69,397 ± 10,161 |
| Abz-EPD-I-SGSKQ(dpnp)S (Bid site with P2′ Gly) | 0.65 ± 0.18 | 59.67 ± 2.92 | 10,915 ± 3,101 | 5.11 ± 0.27 | 22.06 ± 2.67 | 231,449 ± 30,585 |
| Abz-LEYD-I-IGALK(dpnp)S (Phage display sequence) | 2.51 ± 0.16 | 23.48 ± 3.68 | 106,948 ± 18,094 | 0.008 ± 0.0004 | 122.9 ± 6.8 | 61.3 ± 4.5 |

Values presented are the mean ± SD ($n = 3$).
aPeptide substrates include aminobenzoyl (Abz), dinitrophenyl (dnp), and C-terminal serine to enhance peptide solubility. Arrow indicates P1–P1′ bond and cleavage site.
hGrB efficiently killed mouse lymphoma cells containing Bid (EC50 2.5 U/ml), but was >1,000-fold less cytotoxic toward lymphoma cells lacking Bid (Fig. 2 C, left). In contrast, mGrB killed the Bid+/+ and Bid−/− cells with similar efficiency, indicating that Bid cleavage is not essential for mGrB cytotoxicity (Fig. 2 C, right). These observations cannot be explained by differences in procaspase 3 levels between these lines or by differences in the ability of mGrB or hGrB to cleave procaspase 3 either in vitro or in cell extracts (compare Fig. 2 B and Fig. S3). It is also unlikely that mGrB can circumvent Bid by directly and fully activating procaspase 3, as z-VAD blocks the second cleavage event when procaspase 3 is exposed to mGrB (Fig. 2 B and Fig. S3). Collectively, the aforementioned results indicate that mGrB and hGrB have similar but distinct substrate specificities and that they trigger death differently.

**Substrate phage display confirms that hGrB and mGrB have distinct specificities**

To compare the substrate specificities of hGrB and mGrB, we used substrate phage display. Phage carry a variable (randomized) nonameric peptide linked to a His tag, fused to a coat protein. Phage adsorbed to nickel-agarose are treated with protease, and cleaved phage are analyzed after several rounds of capture and release.

The granzymes were used to probe a library in which the fourth residue of the nonamer had been fixed as Asp. As shown in Fig. 3, phage enriched by hGrB treatment displayed a P4-P3-P2-P1-P1′-P2′-P3′ consensus sequence, [I/V][G/E]ADVLV. This closely matches the P4-P1 sequence previously identified by combinatorial peptide analysis (Thornberry et al., 1997; Harris et al., 1998) and validates the phage display approach. In contrast, treatment with mGrB yielded the consensus sequence [I/L]X[F/Y]DXGXV. Specifically, the preferences at the P4, P2, and P2′ positions are different between mGrB and hGrB. mGrB shows an equal preference for Ile or Leu at P4 and an aromatic residue at P2, whereas hGrB strongly prefers Ile at P4 and has a relaxed requirement at P2. mGrB also has a very strong preference for Gly at P2′, whereas hGrB has no obvious preference at this position.

To confirm that mGrB can cleave a substrate with the aforementioned characteristics, we synthesized a quenched-fluorescence substrate peptide based on one of the phage sequences that met the consensus [L/I]X[F/Y]DXGX. This peptide abz-LEYDLGALK(dnp)S was cleaved by both mGrB and hGrB, but kinetic analysis showed that it is a 370-fold better substrate for mGrB (Table I, compare specificity constants). These results show that the consensus substrate sequences for hGrB and mGrB differ at the key P4, P2, and P2′ positions and indicate structural differences in the corresponding pockets in the catalytic clefts of the two enzymes.

**Efficient cleavage of Bid by mGrB requires a P2′ Gly**

As shown in Fig. 2, mGrB cleaves Bid poorly but procaspase 3 relatively well. The substrate phage display results suggest that mGrB requires Gly at the P2′ to efficiently cleave substrates, but both mouse and human Bid have Glu at this position.

To determine whether P2′ Gly enhances cleavage by mGrB, we synthesized a peptide substrate based on the GrB cleavage site in mouse Bid (IEPD†SESQ) and a derivative with P2′ Gly (IEPD†SGSQ). Both hGrB and mGrB cleaved the wild-type (wt) Bid substrate, but hGrB cleaved it 40-fold more efficiently (Table I). This is consistent with the 30-fold difference in the ability of the two proteases to cleave IETD-pNA (Fig. 2 A). In contrast, mGrB cleaved the P2′ Gly substrate sevenfold better than the wt Bid substrate, whereas hGrB showed a threefold improvement over cleavage of the wt sequence, consistent with the slight overrepresentation of Gly at P2′ in the phage display data (Fig. 3). Thus, mGrB prefers P2′ Gly in natural substrates, and its poor cleavage of Bid can be explained partly by lack of Gly at this position. Given the conservation of the P4-P1 sequence in Bid and procaspase 3 (IEXD), these results also explain why procaspase 3 is apparently a better substrate of mGrB than Bid (Fig. 2 B): mouse procaspase 3 has a P2′ Gly at its GrB cleavage site.

**mGrB can be “humanized” by alteration of its S4/S3 subsite**

The inability of mGrB to cleave after IETD suggested differences between mGrB and hGrB in the substrate binding cleft, presumably in the pockets that interact with the side chains of...
the P4, P3, or P2 residues of a substrate. Inspection of the structure of hGrB bound to the tetrapeptide aldehyde inhibitor IEPD-CHO (Rotonda et al., 2001) revealed that Asn218 in the S4 pocket forms hydrogen bonds with the P3 Glu of the substrate, whereas Tyr174 in the S4 pocket undergoes hydrophobic interactions with P4 Ile of the substrate (Fig. 4 A). These two residues are conserved in rat GrB and have been shown to influence substrate specificity (Ruggles et al., 2004). In contrast, they are not conserved in mGrB (Fig. 4 B, Arg174 and Lys218). Thus, we predicted that mutating mGrB toward hGrB by replacing Arg174 with Tyr and Lys218 with Asn would enable it to more efficiently cleave IETD and Bid.

As shown in Fig. 5 A, mutated mGrB retained the ability to cleave AAD-sbzl and showed substantially enhanced activity on IETD-pNA, with $k_{cat}/K_m$ values on both substrates similar to those of hGrB (compare Fig. 5 A with Fig. 2 A). In addition, the mutant mGrB showed enhanced ability to cleave Bid, together with a slight increase in the ability to cleave procaspase 3 (Fig. 5 B). This translated into an increased ability to kill the Bid-/- lymphomas (Fig. 5 C). Interestingly, the mutated mGrB showed an increased ability to kill the Bid-+-/+- lymphomas (Fig. 5 C), suggesting that rather than being simply converted to hGrB selectivity, it has gained the ability to cleave hGrB-specific targets (e.g., Bid) while retaining the ability to cleave mGrB-specific targets. Finally, mutant mGrB showed 100-fold enhanced ability to kill P815 cells, with similar efficiency to hGrB (Fig. 5 D, left).

At present, the reason for the difference in mutant mGrB killing of the lymphoma cells (two- to fourfold increase) compared with P815 cells (100-fold increase) is unclear, but it is possible that the altered mGrB cleaves a target in P815 cells that is absent from the lymphoma cells. Nevertheless, collectively, the aforementioned results confirm that mGrB has a substrate binding cleft that is structurally distinct from hGrB, which explains its different substrate specificity profile and killing mechanism.

**Serpins that regulate hGrB and mGrB cytotoxicity are not conserved**

hGrB is regulated by the intracellular protease inhibitor, PI-9, a member of the serpin superfamily (Bird et al., 1998; Hirst et al., 2003). The serpin inhibitory mechanism requires recognition of an exposed reactive center loop (RCL) as a potential substrate by a cognate protease, followed by cleavage between the P1 and P1’ residues. This triggers conformational change in the serpin, distorting the active site of the protease and trapping an intermediate consisting of the protease bound to the serpin (for review see Gettins, 2002). hGrB cleaves the PI-9 RCL after Glu, consistent with its preference for acidic residues, and is very rapidly trapped (Sun et al., 2001).

Mice have seven PI-9 homologues (Kaiserman et al., 2002), but the counterpart of PI-9 is not immediately obvious. The closest homologue, SPI6, has not been tested with mGrB but inhibits hGrB 20-fold slower than PI-9 (Sun et al., 1997). When overexpressed, SPI6 protects dendritic cells (Medema et al., 2001) and T cells (Phillips et al., 2004) from CL attack and increases the survival of CD8+ memory cells (Phillips et al., 2004). Loss of SPI6 results in diminished survival of CTL (Zhang et al., 2006). However, none of these studies has demonstrated that SPI6 directly or efficiently inhibits mGrB. To determine whether SPI6 is a mouse GrB inhibitor, we identified the cleavage site for mGrB in the SPI6 RCL and measured the kinetics of the interaction, assessed the ability of SPI6 and mGrB to interact in CL extracts, and tested whether SPI6 protects cells against death mediated by purified mGrB and perforin.

The hGrB–PI-9 interaction requires cleavage of the PI-9 RCL at Glu340 (Sun et al., 2001; Fig. 6 A), and mGrB also cleaves PI-9 at this point (unpublished data). N-terminal sequencing of the 6-kD fragment generated by treatment of SPI6 with mGrB or hGrB showed that cleavage occurs at Cys339, adjacent to the predicted P1 Cys340 (Fig. 6 A). This is a previously unrecognized cleavage specificity of GrB and broadens the range of potential substrates.
Although cleavage at Cys339 might allow capture of some mGrB by SPI6, the kinetics of the interaction will indicate whether mGrB is effectively regulated by SPI6 in vivo. Accordingly, we measured the rate constant ($k_{ass}$) and stoichiometry of inhibition of SPI6 and mGrB complex formation (Table II). The results strongly suggest that SPI6 is a poor inhibitor of mGrB. The stoichiometry of inhibition indicates that fewer than one out of five contacts results in mGrB trapping, and the low $k_{ass}$ indicates that complex formation is very slow. SPI6 is even less effective in inhibiting hGrB (Table II). To put these results into context, PI-9 inhibits hGrB with equimolar stoichiometry and a rate of $1.2 \times 10^6 \text{M}^{-1}\text{s}^{-1}$ (Sun et al., 2001). Furthermore, the inhibition of mGrB by SPI6 is slower than the inhibition of hGrB by the viral serpin CrmA (Quan et al., 1995), which does not block GrB-mediated apoptosis in vivo.

Another signature of a serpin–protease interaction is the formation of SDS-stable complexes. For example, when human CLs are lysed, GrB is released from granules and rapidly binds cytosolic PI-9, and because GrB is in excess, essentially all of the PI-9 moves into complex (Fig. 6 B, left; Hirst et al., 2003). Similarly, in extracts of mouse CLs probed with anti-mGrB or anti-SPI6 antibodies, a complex containing mGrB and SPI6 was evident (Fig. 6 B, right). However, less than half of the SPI6 moved into complex, consistent with a less efficient interaction between this serpin and GrB, and indicating that the slow in vitro kinetics are not due to lack of a SPI6 cofactor present in CLs. To confirm that complex formation is GrB dependent, extracts were prepared from CLs taken from mice lacking GrB. No complex was evident in these cells (unpublished data).

If mouse and human GrB are orthologous, PI-9 and SPI6 should provide cross-species protection from GrB-mediated cell death. To test this, we challenged mouse P815 cells expressing SPI6 with hGrB and human SKW6.4 cells expressing PI-9 with mGrB (Fig. 6 C). As expected, PI-9 protected SKW6.4 cells against hGrB (Fig. 6 C, top left), increasing the EC50 >20-fold. SPI6 protected P815 cells against mGrB (Fig. 6 C, bottom right), increasing the EC50 >14-fold. Furthermore, the inactive SPI6T327R hinge mutant did not prevent mGrB-mediated death, indicating that the classic serpin inhibitory mechanism is involved in SPI6 cytoprotection (unpublished data). However, PI-9 did not protect cells against mGrB (Fig. 6 C, top right), nor did SPI6 effectively protect cells against hGrB (Fig. 6 C, bottom left).

Finally, the humanized mutant mGrB almost completely lost its ability to be regulated by SPI6, exhibiting a similar cytotoxicity profile to hGrB on SPI6-expressing cells (Fig. 5 D, right). This is consistent with the alterations to its active site cleft and substrate interactions and emphasizes the high specificity of a cognate serpin–protease interaction. From the aforementioned experiments, we concluded that mGrB is indirectly inhibited by SPI6 and that PI-9 and SPI6 are not functionally interchangeable. These results confirm that mGrB and hGrB have distinct substrate specificities and indicate that they are regulated differently in vivo.

Mouse and human GrA have significantly different cytotoxic potential

The functional differences that we identified between mGrB and hGrB raised the possibility that mGrB by SPI6, the kinetics of the interaction will indicate whether mGrB is effectively regulated by SPI6 in vivo. Accordingly, we measured the rate constant ($k_{ass}$) and stoichiometry of inhibition of SPI6 and mGrB complex formation (Table II). The results strongly suggest that SPI6 is a poor inhibitor of mGrB. The stoichiometry of inhibition indicates that fewer than one out of five contacts results in mGrB trapping, and the low $k_{ass}$ indicates that complex formation is very slow. SPI6 is even less effective in inhibiting hGrB (Table II). To put these results into context, PI-9 inhibits hGrB with equimolar stoichiometry and a rate of $1.2 \times 10^6 \text{M}^{-1}\text{s}^{-1}$ (Sun et al., 2001). Furthermore, the inhibition of mGrB by SPI6 is slower than the inhibition of hGrB by the viral serpin CrmA (Quan et al., 1995), which does not block GrB-mediated apoptosis in vivo.

Another signature of a serpin–protease interaction is the formation of SDS-stable complexes. For example, when human CLs are lysed, GrB is released from granules and rapidly binds cytosolic PI-9, and because GrB is in excess, essentially all of the PI-9 moves into complex (Fig. 6 B, left; Hirst et al., 2003). Similarly, in extracts of mouse CLs probed with anti-mGrB or anti-SPI6 antibodies, a complex containing mGrB and SPI6 was evident (Fig. 6 B, right). However, less than half of the SPI6 moved into complex, consistent with a less efficient interaction between this serpin and GrB, and indicating that the slow in vitro kinetics are not due to lack of a SPI6 cofactor present in CLs. To confirm that complex formation is GrB dependent, extracts were prepared from CLs taken from mice lacking GrB. No complex was evident in these cells (unpublished data).

If mouse and human GrB are orthologous, PI-9 and SPI6 should provide cross-species protection from GrB-mediated cell death. To test this, we challenged mouse P815 cells expressing SPI6 with hGrB and human SKW6.4 cells expressing PI-9 with mGrB (Fig. 6 C). As expected, PI-9 protected SKW6.4 cells against hGrB (Fig. 6 C, top left), increasing the EC50 >20-fold. SPI6 protected P815 cells against mGrB (Fig. 6 C, bottom right), increasing the EC50 >14-fold. Furthermore, the inactive SPI6T327R hinge mutant did not prevent mGrB-mediated death, indicating that the classic serpin inhibitory mechanism is involved in SPI6 cytoprotection (unpublished data). However, PI-9 did not protect cells against mGrB (Fig. 6 C, top right), nor did SPI6 effectively protect cells against hGrB (Fig. 6 C, bottom left).

Finally, the humanized mutant mGrB almost completely lost its ability to be regulated by SPI6, exhibiting a similar cytotoxicity profile to hGrB on SPI6-expressing cells (Fig. 5 D, right). This is consistent with the alterations to its active site cleft and substrate interactions and emphasizes the high specificity of a cognate serpin–protease interaction. From the aforementioned experiments, we concluded that mGrB is indirectly inhibited by SPI6 and that PI-9 and SPI6 are not functionally interchangeable. These results confirm that mGrB and hGrB have distinct substrate specificities and indicate that they are regulated differently in vivo.

Mouse and human GrA have significantly different cytotoxic potential

The functional differences that we identified between mGrB and hGrB raised the possibility that such interspecies differences...
would also be evident in other granzymes. Although mouse and human GrA cleave the peptide substrate benzyloxy-carbonyl-Lys-thiobenzyl ester with similar efficiency (Fig. 7 A; Odake et al., 1991), structural and substrate preference analysis of GrA has identified differences between the mouse and human enzymes in the active site cleft (Bell et al., 2003). This study identified an optimal P4-P1 substrate for hGrA as V ANR, whereas the optimal mGrA substrate was identified as GYFR.

Mutation of the hGrA S4 and S3 pockets converted it to a mouse-like GrA (Bell et al., 2003). To determine whether these structural differences translate into differences in cytotoxic potential, we compared the ability of mGrA and hGrA to kill human or mouse cells in the presence of perforin. We used two different death assays: our standard MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) test, which measures loss of mitochondrial respiration (Fig. 7 C), and 51Cr release, which measures loss of membrane integrity (Fig. 7 D). As shown in Fig. 7 (C and D), mGrA efficiently killed mouse and human cells, but hGrA did not. mGrA-induced death was perforin dependent, as cells exposed to mGrA alone survived (Fig. 7 C). The inability of hGrA to kill cells was not related to the source of the protease, as both recombinant and native forms were used. All of the hGrA used was in the physiological 60-kD dimeric form, which could be reduced to the 30-kD monomeric form (Fig. 7 B). Monomeric hGrA also failed to kill cells (unpublished data).

Discussion

GrA and GrB are believed to be the primary cytoxins in human and mouse CLs. The evidence presented here clearly demonstrates substantial interspecies distinctions that suggest caution when using mouse models to elucidate the molecular and pathophysiological functions of these proteases in humans. For example, loss of GrB may be much more devastating to humans than the mild phenotype of GrB-deficient mice would suggest, given that hGrB is more efficient than mGrB and that hGrA is apparently nonlethal and could not compensate for GrB absence.

Such interspecies differences between granzymes are illustrated by the GrB–Bid interaction, which indicates that distinct death pathways are initiated by hGrB and mGrB (Fig. 8 A). Our results show that hGrB is a much more effective killer than mGrB because it can cleave and activate Bid, whereas mGrB cleaves Bid poorly and does not require it for initiating apoptosis. The requirement for Bid in hGrB-mediated killing is not an artifact arising from its use on mouse target cells, as Bcl-2 overexpression in human cells blocks hGrB cytotoxicity but can be relieved by Bid coexpression (Waterhouse et al., 2006). The failure of hGrB to kill in the absence of Bid indicates that it lacks the capacity to independently and fully activate effector caspases, as suggested previously (Goping et al., 2003; Sutton et al., 2003). Its ability to cleave other substrates must also be
insufficient to cause death. In contrast, mGrB probably directly activates another effector caspase, such as procaspase 7, or it relieves IAP inhibition of caspase 3 independently of Bid. It may also cause caspase-independent death by cleaving substrates such as ICAD or as-yet-undefined mitochondrial targets (Thomas et al., 2001).

The differences between hGrB and mGrB are also emphasized by our ability to humanize mGrB and improve its capacity to cleave substrates such as ICAD or as-yet-undefined mitochondrial targets (Thomas et al., 2001). The differences between hGrB and mGrB are also extended to their regulation, as indicated by differences between PI-9 and SPI6. PI-9 is an efficient hGrB inhibitor that protects CLs and mGrB does not require Bax or Bak for cytotoxicity, whereas hGrB does (Thomas et al., 2001; Cartron et al., 2003).

Similarly, hGrA and mGrA do not appear to be functionally equivalent, as we have shown that mGrA is cytotoxic and that hGrA is not. This is supported by several other lines of evidence. Modeling of mGrA on the structure of hGrA has identified differences in their active site clefts, substantiated by differences in peptide substrate preference and the conversion of hGrA to an mGrA-like protease by mutation of the S4/S3 pockets (Bell et al., 2003). Early work showed that mGrA is cytotoxic when produced with perforin in rat basophilic leukemia cells (Shiver et al., 1992), and many studies on the mechanisms of GrA-mediated death have used CTL and target cells from mice (Pardo et al., 2002, 2004). In contrast, recent studies using specific inhibitors show that hGrA is a minor contributor to CL cytotoxicity (Mahrus and Craik, 2005). Such findings do not necessarily overturn the idea that hGrA engages apoptotic pathways by cleaving specific subcellular proteins and generating reactive oxygen species (Pardo et al., 2004; Martinvalet et al., 2005), but they suggest that it does so much less efficiently than mGrA and that it is not sufficient to induce cell death.
bystanders from misdirected GrB (Sun et al., 1996; Bird et al., 1998; Hirst et al., 2003), and SPI6 is a putative counterpart of PI-9 (Sun et al., 1997; Medema et al., 2001; Phillips et al., 2004). Mice lacking SPI6 have fewer CTL, and remaining CTL have fewer granules and less evidence of cytoplasmic mGrB (Zhang et al., 2006). Crossing SPI6-deficient mice with mGrB-deficient mice rescues the CTL defect, but because the latter mice also lack several mGrB paralogues (Pham et al., 1996), it cannot be assumed that SPI6 directly controls mGrB. Although the accumulating evidence is consistent with a cytoprotective role for both PI-9 and SPI6 in CLs, our present work strongly suggests that the question of the mechanism of cytoprotection by SPI6 remains open, as it is not an effective mGrB inhibitor. Given that other mGrB paralogues are cytotoxic, four possibilities exist: the primary target of SPI6 is a cytotoxic mGrB parologue; SPI6 simultaneously controls multiple mGrB paralogues through a one-size-fits-all RCL; mGrB or paralogues activate a downstream apoptotic protease, which is efficiently inhibited by SPI6 (and not activatable by hGrB); or SPI6 protects granule integrity independently of granzyme inhibition (in which case, PI-9 would be predicted to control GrB and independently protect granule integrity). We consider the last two possibilities more likely because they explain why the rat, which has a more human-like GrB (Harris et al., 1998), has an orthologue of SPI6 rather than PI-9.

Among mammals, the multiple granzyme and serpin genes found in rodents appear to be the exception rather than the rule (Fig. 8 B), and it is evident that GrB and PI-9 paralogues emerged after divergence of Lagomorpha and Rodentia. A priori, the disappearance of the PI-9 RCL sequence from rodents suggests a fundamental change to the structure of mGrB, which we have confirmed by demonstrating that mGrB is catalytically distinct from hGrB and is not controlled by PI-9. Conversely, we have shown that hGrB is not controlled by SPI6. Although mGrB has changed, the GrB cleavage site in mouse Bid is conserved and is accessible to hGrB. Thus, it can be surmised that mGrB has lost cytotoxicity rather than hGrB gaining it. Conservation of the mouse Bid cleavage site suggests that another protease attacks it or that it serves another function in the molecule.

Why have these changes occurred in rodents? Given its role in immunity, the simplest explanation is that mGrB has evolved to target a virulence factor from a particular pathogen or to avoid inhibition by a specific pathogen protein. Specific targeting of virulence factors has been demonstrated for another leukocyte protease, neutrophil elastase (Weinrauch et al., 2002). Duplication of mGrB to generate paralogues may have allowed compensating cytotoxic mechanisms to evolve and/or multiple virulence factors to be targeted. The former possibility is supported by the reported cytotoxic functions of GrC and GrF (Revell et al., 2005). The appearance of cytotoxic mGrB paralogues may have then driven the evolution of cognate PI-9 paralogues.

Although functioning primarily as a cytotoxin, GrB probably has other roles. For example, in humans it is found in testis and has been implicated in reproduction (Hirst et al., 2001). It may also be involved in extracellular matrix remodeling (Buzza et al., 2005). With multiple substrates and roles, it is easy to envisage that particular functions of GrB may have devolved to separate mGrB paralogues in rodents. For example, mouse granzyme N appears to be restricted to the testis and may have assumed the testicular role of hGrB (Takano et al., 2004).

In closing, we have shown that mGrB is structurally and enzymatically distinct from hGrB and has a different killing mechanism. We have also shown that human GrA is not cytotoxic, whereas mGrA is substantially cytotoxic. Such species differences may also extend to granzymes M and K, but appropriate comparisons have yet to be made. It may be that the overall killing efficiency of human and mouse CLs is comparable and that the loss of GrB cytotoxicity in the mouse has been offset by a gain in GrA cytotoxicity or the evolution of GrB paralogues. Nevertheless, use of a granzyme from one species on cells or extracts from another species may produce misleading results because key substrates are missing or are inefficiently cleaved because recognition sites are not conserved. Use of mice to test inhibitors of human granzymes will fail because differences in active site topology of the mouse enzymes will prevent inhibitor binding. Likewise, use of mice to study viral infection may be complicated, as conserved virus inhibitors (e.g., SPI2/CrmA, Bcl-2 homologues, and AdL4-100K homologues) will interact differently with or fail to control mouse granzymes. Finally, use of mouse models to study the impact of granzymes on tumorigenesis is also problematic because the species-specific death pathways and substrates outlined here imply that tumors will subvert the immune system differently in mice and humans by up- or down-regulating different proteins.

Materials and methods

Granzymes and serpins

Recombinant serpins were produced in Pichia pastoris as described previously (Sun et al., 1995, 1997). Recombinant granzymes were also produced from P. pastoris (Sun et al., 1999, 2004). To improve expression levels, the wt mGrB cDNA was modified by QuickChange site-directed mutagenesis (Stratagene) to remove a cryptic polyadenylation site, using the oligonucleotide 5′-CAGTGTGAAGGAGTAGATACGTCATCITGTTG-GGCGC-3′ and its complement. The S4/S3 substrates in mGrB were mutated using the oligos 5′-GAGTCTCATTATTAAATATACAAAACACATCAG-3′ and its complement (R174Y) and 5′-TCTATATCGTTAATAGTGTTTTAC-3′ and its complement (K218NI). Activity of recombinant GrB was assessed by cleavage of the peptide substrate benzoyloxycarbonyl-AlaAlaAsp-phenyl benzoyl ester (Sun et al., 1999, 2004). The specific activity of hGrB was 90 U/μg, and the specific activity of mGrB was 120 U/μg. The proportion of active enzyme in each batch of purified protein was estimated by the ability to complex with PI-9 or SPI6. Routinely, >90% of granzyme in a batch could complex with the appropriate serpin.

Native human GrA was from lymphokine-activated killer cells. Activity of GrA was assessed by cleavage of the substrate benzoyloxycarbonyl-Lys-phenyl benzoyl ester.

Kinetic analysis of substrate cleavage by granzymes and inhibition by serpins

Quenched fluorescence substrates were synthesized and used as described previously (Sun et al., 2001). Activity of granzymes on the peptide substrates Boc-ADP-ksi benzyl ester (BIOMOL Research Laboratories, Inc.) and IETD-pNA (Calbiochem) was assessed as described previously (Sun et al., 2001). Inhibition of granzymes by serpins was measured using standard approaches (Hopkins and Stone, 1995; Sun et al., 2001). Granzyme cleavage sites in SPI6 and PI-9 were identified by N-terminal sequencing (Sun et al., 2001).

Production of granzyme substrates via in vitro transcription and translation

125I-labeled mouse procapase 3 or mouse Bid was produced from cDNAs in the expression vector pSVT via in vitro transcription and translation (Sun et al., 2004). Cleavage by granzymes was assessed by adding a specified
amount of protease directly to the translation mix and incubating for 30 min at 37°C. The caspase inhibitor z-VAD was obtained from Calbiochem. Products were separated by SDS-PAGE and visualized by fluorography.

**Analysis of granzyme substrate specificity by phage display**

Construction of substrate libraries based on bacteriophage T7 used the T7Select-1b phage display system (Novagen). Each library was made by synthesizing a degenerate oligonucleotide, annealing it to complementary half-site oligonucleotides, ligating it with a linker and splitting the heteroduplex into two arms, and adding it to a T7 phage packaging extract. The half-site oligonucleotides were 5'-GCCGGCTTGGATGAGACG-3' and 5'-AGCTGGATGGATGGATGATG-3'. One library was constructed using the degenerate oligonucleotide 5'-AATCTCCTACCTACCAGCCGCGC(NNNK)CA-TCCACATCCATCCACA-3' (where N represents any nucleotide and K represents T/C). This added a randomized nonameric peptide and a hexahistidine tag to the C terminus of the 108C coat protein. The complexity of this “random” library was 7 × 10⁸ plaque-forming units. Another library was constructed using 5'-AATCTCCTACCTACCAGCCGCGC(NNNK)GAC(NNNK)CATCCACATCCATCCACA-3'. This encoded an aspartate near the middle of the randomized peptide. The complexity of this “fixed” library was 4 × 10⁸ plaque-forming units. Each library was amplified to >10¹⁵ plaque-forming units. About 10⁴ plaque-forming units of amplified plasmid were used to nick-transfect Sepharose beads at 4°C. Unbound plasmid was removed by washing the beads in phosphate-buffered saline containing 850 mM NaCl and 0.1% (vol/vol) Tween 20. After two further washes in phosphate-buffered saline containing 1 mM MgSO₄, the suspension was split into two parts (treatment and control; control treatments were performed to assess the extent of plasmid release from the beads in the absence of protease). 200 nM granzyme was added to the treatment tube, and both tubes were incubated overnight at 37°C. Plaque-forming units in the supernatants representing cleaved or released plasmid were then counted and amplified to form sublibraries for the next round of selection. Plasmid remaining bound to the beads was eluted with 0.5 M imidazole, and plaque-forming units were counted to assess cleavage efficiency. After several selection rounds, individual plaques were chosen at random for sequence analysis. Phage DNA was amplified by PCR using dedicated primers (T7Select cloning kit; Novagen). Sequencing of PCR products using the same primers was performed using the Big Dye 3.1 kit (GE Healthcare). Sequence analysis. Phage DNA was ampliﬁed by PCR using dedicated primers (T7Select cloning kit; Novagen). Sequencing of PCR products using the same primers was performed using the Big Dye 3.1 kit (GE Healthcare).

The sequencing results were analyzed to determine the statistical distribution of each amino acid at each position of the nonamer (Matthews et al., 1994), allowing for the redundancy of the code, the fact that only 32 out of 64 codons are represented by NNK, and the exclusion from the analysis of any sequences encoding a stop codon in the nonamer. In a bi-nominal distribution of amino acids, ∆ω yields the diﬀerence of the observed frequency from the expected frequency in terms of standard deviations:

$$\Delta \omega = \frac{\text{Obs}(x) - n \times \text{P}(x)}{\sqrt{n \times \text{P}(x) \times (1 - \text{P}(x))}}$$

where Obs(x) is the number of times amino acid x occurs in the selected sequences, P(x) is the theoretical probability of amino acid x occurring, and n is the total number of sequences analyzed.

**Cells, culture, and transfections**

Human YT and Jurkat cells were maintained as described previously (Bird et al., 1998). Eμ-myc/bid−/− and Eμ-myc/bid+/+ mouse B lymphomas (Waterhouse et al., 2005) were obtained from R. Johnstone (Peter MacCallum Cancer Institute, Melbourne, Australia). Human SKW6.4 and mouse EL4 and YAC-1 cells were maintained in Dulbecco’s modiﬁed Eagle medium containing 10% heat-inactivated fetal calf serum, 2 mM glutamine, and 55 µM β-mercaptoethanol. PBL and P815 cells were maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum, 2 mM glutamine, and 55 µM β-mercaptoethanol. Isolation and culture of mouse splenocytes followed standard procedures.

To generate SKW6.4 cells stably expressing PI-9, a PI-9 expression vector (Bird et al., 1998) was cotransfected by electroporation with a plasmid expressing c-myc and a plasmid expressing a ΔC29Δ32 myb/bid (Dr. R. Johnstone for providing the Eμ-myc cells, and Dr. N. Waterhouse [Peter McCallum Cancer Institute] for advice and discussions). The work was supported by project grants to P.I. Bird, J.C. Whisstock (284233), and J.A. Trapani from the National Health and Medical Research Council (Australia). We thank K. Sedelies for assistance with 51Cr assays, Q. Zhou for help with construction of mutant mGrB, Dr. R. Johnstone for providing the Eμ-myc cells, and Dr. N. Waterhouse (Peter McCallum Cancer Institute) for advice and discussions.

Submitted: 14 June 2006
Accepted: 19 October 2006

**References**

Adrain, C., B.M. Murphy, and S.J. Martin. 2005. Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B. J. Biol. Chem. 280:4663–4667.

Andrade, F., L. Casciola-Rosen, and A. Rosen. 2003. A novel domain in adenovirus L4-100K is required for stable binding and efficient inhibition of human granzyme B: possible interaction with a species-specific exosite. J. Virol. 77:1466–1476.

Bell, J.K., D.H. Goetz, S. Mahar, J.L. Harris, R.J. Fletterick, and C.S. Craik. 2003. The oligomeric structure of human granzyme A is a determinant of its extended substrate specificity. Nat. Struct. Biol. 10:527–534.

Huang et al., 1997. 1.25 × 10⁸ P815 cells were electroporated at 330 µF and 350 V with either pEFpuro/FlagSpI6 or pEFpuro/FlagSpI6T327R vectors linearized with Sall. Transfected pools were grown for 3 d in 1.1 µg/ml puromycin, and subsequently 45 SpI6 and 28 SpI6T327R lines were cloned by limiting dilution in puromycin selection. Clones were scored for relative SpI6 expression by indirect immunofluorescence using the e-FLAG M2 antibody. Expression was confirmed by immunobluiting using rabbit anti-ber (R25) raised to recombinant SpI6. This antigen does not recognize the human granzyme B (Serpin9b, Serpin9e, Serpinb6, Serpinb5b, and Serpinb1) and can be considered specific for SpI6.

**Cytoxicity assays**

Cell death mediated by granzymes and recombinant perforin was assessed as previously described (Sun et al., 2004; Bird et al., 2005). Recombinant perforin was produced using a baculovirus expression system (Jiu et al., 1994). Recombinant SLO was prepared and used according to Walew et al. (2001).

**Preparation of cell extracts, antibodies, and immunoblotting**

For analysis of serpin complexes, cells were lysed in either 1 volume of Laemmli sample buffer (LSB) or 1/2 volume of NP-40 lysis buffer (50 mM Tris HCl, pH 8.0, 10 mM EDTA, and 1% [vol/vol] Nonidet P40), followed by incubation at 37°C for 10 min, after which 1/2 volume of 2× LSB was added. Viscosity was reduced by mechanically shearing the DNA using a needle and syringe. For analysis of caspase 3 cleavage, cells were lysed in NP-40 lysis buffer containing 1 µg/ml pepstatin, 1 µg/ml leupeptin, 1 µg/ml aprotinin, and 10 µg/ml PMSF, and a postnuclear supernatant was prepared by centrifugation at 16,000 g. Antibodies to PI-9 (R15) and hGrA (2CS501) and a hybridoma supernatant were used for immunoblotting at 1:2,000 and 1:100, respectively. A rat monoclonal antibody against mGrB was obtained from ebioscience (clone 16G6) and was used at 1:1000. Goat anti-actin sera (Santa Cruz Biotechnology, Inc.) was used at 1:1,000. Rabbit antisera to SpI6 (R25) and hGrA (R045) was raised against recombinant protein purified from P. pastoris following standard procedures and was used at 1:1,000. Rabbit antisera to caspase 3 (Cell Signalling Technology) was used at 1:100. HRP-conjugated secondary antibodies was used at 1:5,000 and detected using enhanced chemiluminescence.

**Image acquisition and manipulation**

Images of blots were initially captured on x-ray films, which were subsequently scanned into Photopaint (Corel). Adjustments to brightness or contrast of digital images were applied to the whole image. No nonlinear adjustments were made.

**Online supplemental material**

Fig. S1 shows a comparison of methods used to assess cell survival after GrB treatment. Fig. S2 shows a comparison of uptake of mGrB and hGrB into target cells. Fig. S3 shows GrB-mediated caspase 3 cleavage in Bid+/+ or Bid−/− mouse B cell lymphoma extracts. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200606073/DC1.

We thank K. Sedelies for assistance with 51Cr assays, Q. Zhou for help with construction of mutant mGrB, Dr. R. Johnstone for providing the Eμ-myc cells, and Dr. N. Waterhouse (Peter McCallum Cancer Institute) for advice and discussions. This work was supported by project grants to P.I. Bird, J.C. Whisstock (284233), and J.A. Trapani from the National Health and Medical Research Council (Australia).

Submitted: 14 June 2006
Accepted: 19 October 2006
Bird, C.H., V.R. Sutton, I. Sun, C.E. Hirst, A. Novak, J.A. Trapani, and P.I. Bird. 1998. Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. *Mol. Cell. Biol.* 18:6587–6598.

Bird, C.H., I. Sun, K. Ung, D. Karambilas, J. Whisstock, J.A. Trapani, and P.I. Bird. 2005. Catonic sites on granzyme B contribute to cytotoxicity by promoting its uptake into target cells. *Mol. Cell. Biol.* 25:7854–7867.

Buzza, M.S., L. Zamurs, J. Sun, C.H. Bird, A.I. Smith, J.A. Trapani, C.J. Froelich, E.C. Nice, and P.I. Bird. 2005. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. *J. Biol. Chem.* 280:23554–23558.

Cartron, P.F., P. Juin, L. Oliver, S. Martin, K. Melfahl, and F.M. Vallette. 2003. Nonredundant role of Bax and Bak in Bcl-mediated apoptosis. *Mol. Cell. Biol.* 23:4701–4712.

Gettins, P.G. 2002. Serpin structure, mechanism, and function. *Chem. Rev.* 102:4751–4804.

Goping, I.S., M. Barry, P. Liston, T. Sawchuk, G. Constantinescu, K.M. Michalak, C.H. Bird, V.R. Sutton, J.A. Trapani, K.L. Loveland, and P.I. Bird. 2003. The differential contribution of granzyme A and/or granzyme B in CTL-mediated target cell lysis. *J. Cell Biol.* 167:457–468.

Pham, C.T.N., D.M. Maclvor, B.A. Hug, J.W. Heusel, and T.J. Ley. 1996. Long-range disruption of gene expression by a selectable marker cassette. *Proc. Natl. Acad. Sci. USA.* 93:13090–13095.

Phillips, T., J.T. Opferman, R. Shah, N. Liu, C.J. Froelich, and P.G. Ashton-Rickhardt. 2004. A role for the granzyme B inhibitor serine protease inhibitor 6 in CD8+ memory cell homeostasis. *J. Immunol.* 173:3801–3809.

Pinkoski, M.J., N.J. Waterhouse, J.A. Heibein, B.B. Wolf, T. Kuwana, J.C. Goldstein, D.D. Newmeyer, R.C. Bleackley, and D.R. Green. 2001. Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway. *J. Biol. Chem.* 276:12000–12007.

Quan, L.T., A. Caputo, R.C. Bleackley, D.J. Pickup, and G.S. Salvesen. 1995. Granzyme B is inhibited by the cowpox virus serpin cytokine response modifier A. *J. Biol. Chem.* 270:10377–10379.

Revell, P.A., W.J. Grossman, D.A. Thomas, X. Cao, R. Behl, J.A. Ratner, Z.H. Lu, and T.J. Ley. 2005. Granzyme B and the downstream granzymes C and/or F are important for cytotoxic lymphocyte functions. *J. Immunol.* 174:2124–2131.

Rotonda, J., M. Garcia-Calvo, H.G. Bull, W.M. Geissler, B.M. McKeever, C.A. Willoughby, N.A. Thornberry, and J.W. Becker. 2001. The three-dimensional structure of human granzyme B compared to caspase-3, key mediators of cell death with cleavage specificity for aspartic acid in P1. *Chem. Biol.* 8:357–368.

Ruggles, S.W., R.J. Fleetterick, and C.S. Craik. 2004. Characterization of structural determinants of granzyme B reveals potent mediators of extended substrate specificity. *J. Biol. Chem.* 279:30751–30759.

Russell, J.H., and T.J. Ley. 2002. Cytolymphocyte-mediated cytotoxicity. *Annu. Rev. Immunol.* 20:323–370.

Schechter, I., and A. Berger. 1967. On the size of the active site in proteases. *Biochemistry.* 7:1133–1142.

Shiver, J.W., L. Su, and P.A. Henkart. 1992. Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolsin and granzyme A. Cell. 71:315–322.

Sun, J., P. Coughlin, H. Salem, and P. Bird. 1995. Production and characterization of recombinant human proteinase inhibitor 6 expressed in Pichia pastoris. *Biotechnol. Bioeng.* 47:28–34.

Sun, J., C.H. Bird, V. Sutton, L. McDonald, P.B. Coughlin, T.A. De Jong, J.A. Trapani, and P.I. Bird. 1996. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytolytic lymphocytes. *J. Biol. Chem.* 271:27802–27809.

Sun, J., L. Ooms, C.H. Bird, V.R. Sutton, J.A. Trapani, and P.I. Bird. 1997. A new family of 10 murine ovalbumin serpins includes two homologs of proteinase inhibitor 8 and two homologs of the granzyme B inhibitor (proteinase inhibitor 9). *J. Biol. Chem.* 272:15434–15441.

Sun, J., C.H. Bird, M.S. Buzza, K.E. McKee, J.C. Whisstock, and P.I. Bird. 1999. Expression and purification of recombinant human granzyme B from Pichia pastoris. *Biochem. Biophys. Res. Commun.* 252:28–34.

Sun, J., C.J. Whisstock, P. Harriott, B. Walker, A. Novak, P.E. Thompson, A.I. Smith, and P.I. Bird. 2000. Importance of the P4' residue in human granzyme B inhibitors and substrates revealed by scanning mutagenesis of the proteinase inhibitor 9 reactive center loop. *J. Biol. Chem.* 275:15177–15184.

Sun, J., C.H. Bird, K.Y. Thia, A.Y. Matthews, J.A. Trapani, and P.I. Bird. 2004. Granzyme B encoded by the commonly occurring human RAH allele retains pro-apoptotic activity. *J. Biol. Chem.* 279:16907–16911.

Sutton, V.R., M.E. Wowk, M. Cancilla, and J.A. Trapani. 2003. Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. *Immunity.* 18:319–329.

Takano, N., H. Matsui, and T. Takahashi. 2004. Granzyme N, a novel granzyme, is induced by the expression of pro-apoptotic Bax and Bak. *J. Immunol.* 172:1785–1795.

Thomas, D.A., L. Scorrano, G.V. Putcha, S.J. Korsmeyer, and T.J. Ley. 2005. Granzyme B and the downstream granzymes C and/or F are important for caspase processing. *J. Biol. Chem.* 280:1252:28–34.

Walev, I., S.C. Bhakdi, F. Hofmann, N. Djonder, A. Valeva, K. Aktories, and S. Bhakdi. 2001. Delivery of proteins into living cells by reversible membrane permeabilization with streptolysin-O. *Proc. Natl. Acad. Sci. USA.* 98:3185–3190.
Waterhouse, N.J., K.A. Sedelies, K.A. Browne, M.E. Wowk, A. Newbold, V.R. Sutton, C.J.P. Clarke, J. Oliaro, R.K. Lindemann, P.I. Bird, et al. 2005. A central role for Bid in granzyme B-induced apoptosis. *J. Biol. Chem.* 280:4476–4482.

Waterhouse, N.J., K.A. Sedelies, V.R. Sutton, M.J. Pinkoski, K.Y. Thia, R.W. Johnstone, P.I. Bird, D.R. Green, and J.A. Trapani. 2006. Functional dissociation of DeltaPsim and cytochrome c release defines the contribution of mitochondria upstream of caspase activation during granzyme B-induced apoptosis. *Cell Death Differ.* 13:607–618.

Weinrauch, Y., D. Drujan, S.D. Shapiro, J. Weiss, and A. Zychlinsky. 2002. Neutrophil elastase targets virulence factors of enterobacteria. *Nature.* 417:91–94.

Willoughby, C.A., H.G. Bull, M. Garcia-Calvo, J. Jiang, K.T. Chapman, and N.A. Thornberry. 2002. Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis. *Bioorg. Med. Chem. Lett.* 12:2197–2200.

Zhang, M., S.M. Park, Y. Wang, R. Shah, N. Liu, A.E. Murmann, C.R. Wang, M.E. Peter, and P.G. Ashton-Rickhardt. 2006. Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. *Immunity.* 24:451–461.
Author/s:  
Kaiserman, D; Bird, CH; Sun, J; Matthews, A; Ung, K; Whisstock, JC; Thompson, PE; Trapani, JA; Bird, PI  

Title:  
The major human and mouse granzymes are structurally and functionally divergent  

Date:  
2006-11-20  

Citation:  
Kaiserman, D., Bird, C. H., Sun, J., Matthews, A., Ung, K., Whisstock, J. C., Thompson, P. E., Trapani, J. A. & Bird, P. I. (2006). The major human and mouse granzymes are structurally and functionally divergent. JOURNAL OF CELL BIOLOGY, 175 (4), pp.619-630. https://doi.org/10.1083/jcb.200606073.  

Persistent Link:  
http://hdl.handle.net/11343/257828  

File Description:  
Published version  

License:  
CC BY-NC-SA